Who Generates More Revenue? Takeda Pharmaceutical Company Limited or ACADIA Pharmaceuticals Inc.

Takeda's Revenue Dominance Over ACADIA: A Decade in Review

__timestampACADIA Pharmaceuticals Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20141200001777824000000
Thursday, January 1, 2015610001807378000000
Friday, January 1, 2016173310001732051000000
Sunday, January 1, 20171249010001770531000000
Monday, January 1, 20182238070002097224000000
Tuesday, January 1, 20193390760003291188000000
Wednesday, January 1, 20204417550003197812000000
Friday, January 1, 20214841450003569006000000
Saturday, January 1, 20225172350004027478000000
Sunday, January 1, 20237264370004263762000000
Monday, January 1, 20244263762000000
Loading chart...

Igniting the spark of knowledge

Revenue Showdown: Takeda vs. ACADIA

In the competitive world of pharmaceuticals, revenue generation is a key indicator of a company's market strength and innovation prowess. Over the past decade, Takeda Pharmaceutical Company Limited has consistently outperformed ACADIA Pharmaceuticals Inc. in terms of revenue. From 2014 to 2023, Takeda's revenue has surged, peaking at approximately 4.26 trillion in 2023, showcasing a robust growth trajectory. In contrast, ACADIA's revenue, while growing, reached a high of around 726 million in the same year. This stark difference highlights Takeda's dominant market position, generating over 5,800 times more revenue than ACADIA in 2023. The data also reveals a consistent upward trend for both companies, although ACADIA's growth is more modest. As we look to the future, the pharmaceutical landscape will continue to evolve, and these revenue trends will be crucial in shaping the industry's competitive dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025